Abstract PR005: Tepotinib + osimertinib in EGFR -mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis von Le, Xiuning, Kim, Tae Min, Guarneri, Valentina, Voon, Pei Jye, Lim, Boon Khaw, Yang, Jinji, Wislez, Marie, Huang, Cheng, Liam, Chong Kim, Mazieres, Julien, Tho, Lye Mun, Hayashi, Hidetoshi, Nhung, Nguyen, Chia, Puey Ling, De Marinis, Fillippo, Raskin, Jo, Zhou, Qinghua, Finochhiaro, Giovanna, Tan, Daniel, Brutlach, Sabine, O'Brate, Aurora, Adrian, Svenja, Berghoff, Karin, Ellers-Lenz, Barbara, Karachaliou, Niki, Wu, Yi-Long

Volltext